Literature DB >> 17374512

Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease.

Dianne McFarlane1.   

Abstract

Parkinson's disease (PD) is a leading cause of neurologic disability in the aged population. Remarkable progress has been made in the past decade to understand the cellular and molecular events that occur in PD. However attempts to unravel the early, initiating factors in the pathogenesis of dopaminergic neurodegeneration and PD have been limited by the lack of a suitable animal model. Models in which there has been genetic or environmental manipulation are not of use in determining the natural cause of a disease. While a large scale prospective human study would be ideal, the relatively low prevalence of PD makes this approach economically and logistically infeasible. Equine pituitary pars intermedia dysfunction (PPID) is a spontaneous, progressive neuroendocrine disease that commonly affects aged horses and ponies. PPID results from neurodegeneration of the dopaminergic periventricular neurons that innervate the intermediate lobe of the pituitary. PPID is 10-20 times more prevalent than PD and may be readily diagnosed without a need for advanced imaging technology. Although the diseases are anatomically distinct, recent evidence suggests the pathogenesis of dopaminergic neuronal damage in PPID may have significant similarities to that of PD. In this review, the similarities and differences in the pathology of neurodegeneration in PPID and PD are compared. The potential utility of the horse as a model of spontaneous dopaminergic neurodegeneration is discussed.

Entities:  

Mesh:

Year:  2007        PMID: 17374512     DOI: 10.1016/j.arr.2007.02.001

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  13 in total

Review 1.  Diabetes, insulin resistance, and metabolic syndrome in horses.

Authors:  Philip J Johnson; Charles E Wiedmeyer; Alison LaCarrubba; V K Ganjam; Nat T Messer
Journal:  J Diabetes Sci Technol       Date:  2012-05-01

Review 2.  Medical implications of obesity in horses--lessons for human obesity.

Authors:  Philip J Johnson; Charles E Wiedmeyer; Nat T Messer; Venkataseshu K Ganjam
Journal:  J Diabetes Sci Technol       Date:  2009-01

3.  Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.

Authors:  D I Rendle; M Duz; J Beech; T Parkin; A E Durham
Journal:  J Vet Intern Med       Date:  2014-10-13       Impact factor: 3.333

4.  Effects of Advanced Age, Pituitary Pars Intermedia Dysfunction and Insulin Dysregulation on Serum Antioxidant Markers in Horses.

Authors:  Agnieszka Żak; Natalia Siwińska; Elżbieta Chełmecka; Barbara Bażanów; Ewa Romuk; Amanda Adams; Artur Niedźwiedź; Dominika Stygar
Journal:  Antioxidants (Basel)       Date:  2020-05-21

5.  Modelling of oscillatory cortisol response in horses using a Bayesian population approach for evaluation of dexamethasone suppression test protocols.

Authors:  Felix Held; Carl Ekstrand; Marija Cvijovic; Johan Gabrielsson; Mats Jirstrand
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-01-23       Impact factor: 2.745

6.  The effect of freeze-thaw cycles on determination of immunoreactive plasma adrenocorticotrophic hormone concentrations in horses.

Authors:  Ke Hu; Allison J Stewart; Ka Y Yuen; Sophia Hinrichsen; Elizabeth L Dryburgh; François-René Bertin
Journal:  J Vet Intern Med       Date:  2020-04-07       Impact factor: 3.333

7.  Pituitary Pars Intermedia Dysfunction and Metabolic Syndrome in Donkeys.

Authors:  Heidrun Gehlen; Bianca Schwarz; Claus Bartmann; Jennifer Gernhardt; Sabita D Stöckle
Journal:  Animals (Basel)       Date:  2020-12-08       Impact factor: 2.752

8.  Equine pituitary pars intermedia dysfunction: Identifying research priorities for diagnosis, treatment and prognosis through a priority setting partnership.

Authors:  Rebecca C Tatum; Cathy M McGowan; Rachel S Dean; Joanne L Ireland
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

9.  Equine pituitary pars intermedia dysfunction: a spontaneous model of synucleinopathy.

Authors:  Jessica S Fortin; Ashley A Hetak; Kelsey E Duggan; Caroline M Burglass; Hailey B Penticoff; Harold C Schott
Journal:  Sci Rep       Date:  2021-08-06       Impact factor: 4.379

Review 10.  Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management.

Authors:  Caroline W Spelta
Journal:  Vet Med (Auckl)       Date:  2015-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.